Full Text Journal Articles by
Author William J Sandborn

Advertisement

Find full text journal articles






Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease.

Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, William J Sandborn, Marc Ferrante, John K Marshall, Walter Reinisch, Parambir S Dulai,

This study evaluated the minimal clinically important short-term improvement in the MM-SES-CD, a novel modified scoring system of the SES-CD, that reliably predicted one-year ER. This post-hoc analysis of two CD clinical trial programs pooled data of 198 participants with baseline ulcers and SES-CD ≥3 who had baseline, post-induction (8-12 ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.

Brian G Feagan, Reena Khanna, William J Sandborn, Séverine Vermeire, Walter Reinisch, Chinyu Su, Leonardo Salese, Haiyun Fan, Jerome Paulissen, Deborah A Woodworth, Wojciech Niezychowski, Bruce E Sands,

<h4>Background</h4>Endoscopy is routine in trials of ulcerative colitis therapies.<h4>Aim</h4>To investigate agreement between central and local Mayo endoscopic subscore (MES) reads in the OCTAVE programme METHODS: Flexible sigmoidoscopy was performed in tofacitinib induction (OCTAVE Induction 1&2, NCT01465763 and NCT01458951), maintenance (OCTAVE Sustain, NCT01458574) and open-label, long-term extension (OCTAVE Open, NCT01470612) studies. ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.

William J Sandborn, James D Lewis, Julian Panes, Edward V Loftus, Geert D'Haens, Zhuqing Yu, Bidan Huang, Ana P Lacerda, Aileen L Pangan, Brian G Feagan,

<h4>Background and aims</h4>Patient-reported outcomes are recommended endpoints in Crohn's disease (CD) trials. The association between patient-reported general well-being relative to symptoms of diarrhea and abdominal pain (AP) in patients with moderate-to-severe CD was explored.<h4>Methods</h4>Patients from 3 randomized, placebo-controlled, double-blind adalimumab or upadacitinib studies with average daily very soft/liquid stool frequency ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

William J Sandborn, Brian G Feagan, Geert D'Haens, Douglas C Wolf, Igor Jovanovic, Stephen B Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, Keith Usiskin, Jean-Frederic Colombel, Loren Laine, Silvio Danese, ,

<h4>Background</h4>Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.<h4>Methods</h4>We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In the 10-week induction period, patients in cohort 1 ... Read more >>

N Engl J Med (The New England journal of medicine)
[2021, 385(14):1280-1291]

Cited: 0 times

View full text PDF listing >>



The relationship between endoscopic and clinical recurrence in postoperative Crohn's disease: a systematic review and meta-analysis.

Alessandro Ble, Cecilia Renzulli, Fabio Cenci, Maria Grimaldi, Michelangelo Barone, Rocio Sedano, Joshua Chang, Tran M Nguyen, Malcolm Hogan, G Y Zou, John K MacDonald, Christopher Ma, William J Sandborn, Brian G Feagan, Emilio Merlo Pich, Vipul Jairath,

<h4>Background and aims</h4>We aimed to quantify the magnitude of the association between endoscopic recurrence and clinical recurrence [symptom relapse] in patients with postoperative Crohn's disease.<h4>Methods</h4>Databases were searched to October 2, 2020 for randomised controlled trials [RCTs] and cohort studies of adult patients with Crohn's disease with ileocolonic resection and anastomosis. ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.

Geert R D'Haens, Walter Reinisch, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Kłopocka, Jochen Klaus, Stefan Schreiber, Dong Il Park, Xavier Hébuterne, Peter Nagy, Fabio Cataldi, Steven W Martin, Satyaprakash Nayak, Anindita Banerjee, Kenneth J Gorelick, William J Sandborn,

<h4>Background</h4>Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment. OPERA II, a multicenter, open-label, phase 2 extension study, assessed the long-term safety and efficacy of ontamalimab in patients with moderate-to-severe ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review.

Nghia H Nguyen, Dominic Picetti, Parambir S Dulai, Vipul Jairath, William J Sandborn, Lucila Ohno-Machado, Peter L Chen, Siddharth Singh,

<h4>Background and aims</h4>There is increasing interest in machine learning-based prediction models in inflammatory bowel diseases (IBD). We synthesized and critically appraised studies comparing machine learning vs. traditional statistical models, using routinely available clinical data for risk prediction in IBD.<h4>Methods</h4>Through a systematic review till January 1, 2021, we identified cohort studies ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease.

Maria Barsky, Joseph Meserve, Helen Le, Angelina Collins, Siddharth Singh, Brigid Boland, William J Sandborn, Parambir S Dulai,

Dig Dis Sci (Digestive diseases and sciences)
[2021, 66(9):3216]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.

Séverine Vermeire, Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, Siddharth Bhatia, Christian Agboton, Maria Rosario, Chunlin Chen, Wenwen Zhang, Krisztina Kisfalvi, William J Sandborn,

<h4>Background and aims</h4>Report results from VISIBLE 2, a randomised, double-blind, placebo-controlled phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD].<h4>Methods</h4>Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.

Bo Shen, Gursimran S Kochhar, Revital Kariv, Xiuli Liu, Udayakumar Navaneethan, David T Rubin, Raymond K Cross, Akira Sugita, André D'Hoore, Jason Schairer, Francis A Farraye, Ravi P Kiran, Philip Fleshner, Joel Rosh, Samir A Shah, Shannon Chang, Ellen Scherl, Darrell S Pardi, David A Schwartz, Paulo G Kotze, David H Bruining, Sunanda V Kane, Jessica Philpott, Bincy Abraham, Jonathan Segal, Rocio Sedano, Maia Kayal, Stuart Bentley-Hibbert, Dino Tarabar, Sandra El-Hachem, Priya Sehgal, James T McCormick, Joseph A Picoraro, Mark S Silverberg, Charles N Bernstein, William J Sandborn, Séverine Vermeire,

Restorative proctocolectomy with ileal pouch-anal anastomosis is an option for most patients with ulcerative colitis or familial adenomatous polyposis who require colectomy. Although the construction of an ileal pouch substantially improves patients' health-related quality of life, the surgery is, directly or indirectly, associated with various structural, inflammatory, and functional adverse ... Read more >>

Lancet Gastroenterol Hepatol (The lancet. Gastroenterology & hepatology)
[2021, 6(10):826-849]

Cited: 0 times

View full text PDF listing >>



A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease.

Parambir S Dulai, Vipul Jairath, Neeraj Narula, Emily Wong, Gursimran S Kochhar, Jean-Frederic Colombel, William J Sandborn,

<h4>Introduction</h4>Cost-effectiveness of biomarker- vs endoscopy-based treat-to-target monitoring in Crohn's disease (CD) is unknown.<h4>Methods</h4>A microsimulation model for CD was built to simulate biomarker (fecal calprotectin) vs endoscopy-based monitoring in a treat-to-target fashion. Published literature in combination with patient-level data from phase 3 clinical trials and population estimates for therapeutic drug monitoring ... Read more >>

Am J Gastroenterol (The American journal of gastroenterology)
[2021, 116(8):1709-1719]

Cited: 0 times

View full text PDF listing >>



Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies.

Lester Tsai, Nghia H Nguyen, Christopher Ma, Larry J Prokop, William J Sandborn, Siddharth Singh,

<h4>Background and aims</h4>Inflammatory bowel diseases (IBD) lead to high morbidity and unplanned healthcare utilization. We conducted a systematic review with meta-analysis to estimate the cumulative incidence of IBD-related (and all-cause) hospitalization in patients with ulcerative colitis (UC) and Crohn's disease (CD).<h4>Methods</h4>Through a systematic review to September 3, 2019, we identified ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases.

Siddharth Singh, Herbert C Heien, Lindsey Sangaralingham, Nilay D Shah, William J Sandborn,

<h4>Introduction</h4>Obesity has been associated with adverse disease-related outcomes and inferior treatment response to biologic agents in patients with inflammatory bowel diseases (IBDs), but its impact on the risk of treatment-related complications is unknown. We performed a cohort study examining the association between obesity and risk of serious infections in biologic-treated ... Read more >>

Clin Transl Gastroenterol (Clinical and translational gastroenterology)
[2021, 12(7):e00380]

Cited: 0 times

View full text PDF listing >>



A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease.

Chung Sang Tse, Siddharth Singh, William J Sandborn,

A growing body of evidence from preclinical, translational, and clinical studies supports a bidirectional relationship within the gut-brain axis that contributes to neurobiological symptoms including anxiety, depression, fatigue, stress, and sleep disturbance. These symptoms have a significant impact on health-related quality of life and functional ability in individuals with inflammatory ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.

Niels Vande Casteele, Brian G Feagan, Douglas C Wolf, Anca Pop, Mohamed Yassine, Sara N Horst, Timothy E Ritter, William J Sandborn,

Therapeutic drug monitoring (TDM) is the measurement of drug and antidrug antibody concentrations in individuals to guide treatment decisions. In patients with Crohn disease (CD), TDM, used either reactively or proactively, is emerging as a valuable tool for optimization of tumor necrosis factor (TNF) antagonist therapy. Reactive TDM is carried ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(8):1346-1355]

Cited: 1 time

View full text PDF listing >>



Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease.

Debashis Sahoo, Lee Swanson, Ibrahim M Sayed, Gajanan D Katkar, Stella-Rita Ibeawuchi, Yash Mittal, Rama F Pranadinata, Courtney Tindle, Mackenzie Fuller, Dominik L Stec, John T Chang, William J Sandborn, Soumita Das, Pradipta Ghosh,

Modeling human diseases as networks simplify complex multi-cellular processes, helps understand patterns in noisy data that humans cannot find, and thereby improves precision in prediction. Using Inflammatory Bowel Disease (IBD) as an example, here we outline an unbiased AI-assisted approach for target identification and validation. A network was built in ... Read more >>

Nat Commun (Nature communications)
[2021, 12(1):4246]

Cited: 0 times

View full text PDF listing >>



Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission.

Hyuk Yoon, Sushrut Jangi, Parambir S Dulai, Brigid S Boland, Vipul Jairath, Brian G Feagan, William J Sandborn, Siddharth Singh,

<h4>Background</h4>Although achieving histologic remission in ulcerative colitis is established, the incremental benefit of achieving histologic remission in patients with Crohn disease (CD) treated to a target of endoscopic remission is unclear. We evaluated the risk of treatment failure in patients with CD in clinical and endoscopic remission by histologic activity ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(8):1277-1284]

Cited: 1 time

View full text PDF listing >>



Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.

Séverine Vermeire, Chinyu Su, Nervin Lawendy, Taku Kobayashi, William J Sandborn, David T Rubin, Irene Modesto, Sean Gardiner, Nicole Kulisek, Haiying Zhang, Wenjin Wang, Julian Panés,

<h4>Background and aims</h4>Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to 5 mg twice daily [BID] versus remaining on 10 mg BID ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(7):1130-1141]

Cited: 1 time

View full text PDF listing >>



Disease Activity Indices for Pouchitis: A Systematic Review.

Rocio Sedano, Tran M Nguyen, Ahmed Almradi, Florian Rieder, Claire E Parker, Lisa M Shackelton, Geert D'Haens, William J Sandborn, Brian G Feagan, Christopher Ma, Vipul Jairath,

<h4>Background</h4>Several indices exist to measure pouchitis disease activity; however, none are fully validated. As an initial step toward creating a validated instrument, we identified pouchitis disease activity indices, examined their operating properties, and assessed their value as outcome measures in clinical trials.<h4>Methods</h4>Electronic databases were searched to identify randomized controlled trials ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.

William J Sandborn, Brian G Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C Wolf, Geert D'Haens,

<h4>Background and aims</h4>This analysis examined the long-term safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC] with ≥ 4 years of follow-up in the phase 2 TOUCHSTONE open-label extension [OLE].<h4>Methods</h4>Patients receiving placebo or ozanimod HCl 0.5 mg or 1 mg during the double-blind period could ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(7):1120-1129]

Cited: 3 times

View full text PDF listing >>



Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease.

Jacob J Rozich, Jiyu Luo, Parambir S Dulai, Angelina E Collins, Lysianne Pham, Brigid S Boland, William J Sandborn, Siddharth Singh,

<h4>Background</h4>The incidence and prevalence of inflammatory bowel diseases (IBD) in older adults are rising. There is a limited comparative assessment of risk of disease- and treatment-related complications in older patients (older than 60 years) with adult-onset (age at disease onset, 18-59 years; AO-IBD) vs elderly-onset IBD (age at disease onset, ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(8):1215-1223]

Cited: 1 time

View full text PDF listing >>



Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases.

Nghia H Nguyen, Xian Zhang, Millie D Long, William J Sandborn, Michael D Kappelman, Siddharth Singh,

<h4>Background and aims</h4>Patient-reported outcome measures (PROMs) provide a wholesome view of patient well-being. We conducted a retrospective cohort study to evaluate whether PROMs inform risk of unplanned healthcare utilization in patients with IBD.<h4>Methods</h4>We identified adult patients with IBD who completed at least two surveys in a large Internet-based cohort within ... Read more >>

Dig Dis Sci (Digestive diseases and sciences)
[2021, :]

Cited: 0 times

View full text PDF listing >>



National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States.

Nghia H Nguyen, Rohan Khera, Parambir S Dulai, Brigid S Boland, Lucila Ohno-Machado, William J Sandborn, Siddharth Singh,

<h4>Background</h4>Inflammatory bowel diseases (IBDs) are associated with substantial health care needs. We estimated the national burden and patterns of financial toxicity and its association with unplanned health care utilization in adults with IBD in the United States.<h4>Methods</h4>Using the National Health Interview survey (2015), we identified individuals with self-reported IBD and ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(7):1068-1078]

Cited: 0 times

View full text PDF listing >>



Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.

William J Sandborn, Brian G Feagan, Silvio Danese, Christopher D O'Brien, Elyssa Ott, Colleen Marano, Thomas Baker, Yiying Zhou, Sheri Volger, Ilia Tikhonov, Christopher Gasink, Bruce E Sands, Subrata Ghosh,

<h4>Background</h4>Ustekinumab is currently approved globally in Crohn's disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn's disease and UC phase 3 programs had similar study designs, facilitating integrated safety analyses.<h4>Methods</h4>Data from 6 ustekinumab phase 2/3 CD and UC studies were pooled, and safety ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(7):994-1007]

Cited: 5 times

View full text PDF listing >>



Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort.

Nghia H Nguyen, Jiyu Luo, Lucila Ohno-Machado, William J Sandborn, Siddharth Singh,

<h4>Background</h4>Fragmentation of care (FoC) may adversely impact health care quality in patients with chronic diseases. We conducted a US nationally representative cohort study to evaluate the burden and outcomes of FoC in hospitalized patients with inflammatory bowel disease (IBD).<h4>Methods</h4>Using Nationwide Readmissions Database 2013, we created 2 cohorts of superutilizer patients ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, 27(7):1026-1034]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

5.1186 s